The FDA’s accelerated approval route has delivered important new drugs to patients quicker, but is opaque and plagued by inconsistencies, says ICER.
Treating enterprise AI as an operating layer
There’s a fault line running through enterprise AI, and it’s not the one getting the most attention. The public conversation still tracks foundation models and benchmarks — GPT versus Gemini, reasoning scores, and marginal capability gains. But in practice, the more durable advantage is structural: who owns the operating layer where intelligence is applied, governed, […]
Making AI operational in constrained public sector environments
The AI boom has hit across industries, and public sector organizations are facing pressure to accelerate adoption. At the same time, government institutions face distinct constraints around security, governance, and operations that set them apart from their business counterparts. For this reason, purpose-built small language models (SLMs) offer a promising path to operationalize AI in […]
Lilly says Foundayo safety confirmed in ACHIEVE-4 trial
Eli Lilly’s ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.
Why having “humans in the loop” in an AI war is an illusion
The availability of artificial intelligence for use in warfare is at the center of a legal battle between Anthropic and the Pentagon. This debate has become urgent, with AI playing a bigger role than ever before in the current conflict with Iran. AI is no longer just helping humans analyze intelligence. It is now an […]
Lilly’s obesity pill heads for diabetes filing after heart risk trial
Eli Lilly’s recently approved obesity pill Foundayo cut the risk of cardiovascular events like heart attack and stroke by 16% versus a form of insulin, new data show, and the company is planning to file …
Beeline raises $300m for BMS drugs, and other biofinancings
Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.
Most patients “won’t see benefit” with Alzheimer’s drugs
A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.
Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
Omnicom Health has stamped its mark on the recently acquired FCB Health New York, rebranding the ad agency as Olixir New York in the aftermath of the mega-merger with Interpublic Group.
Freya Biosciences advances microbial treatment for IVF implantation failure
Freya Biosciences is moving a microbial immunotherapy for IVF implantation failure into mid-stage trials after promising results in healthy volunteers. The Phase 2 study is testing Freya’s candidate, called FB301, in women with vaginal dysbiosis …
6-Year Ransomware Campaign Targets Turkish Homes & SMBs
While enterprises breaches make more headlines, smaller incidents tend to be under-reported, if at all, allowing campaigns to last longer with less disruption.
L2D-Clinical: Learning to Defer for Adaptive Model Selection in Clinical Text Classification
arXiv:2604.13285v1 Announce Type: cross Abstract: Clinical text classification requires choosing between specialized fine-tuned models (BERT variants) and general-purpose large language models (LLMs), yet neither dominates across all instances. We introduce Learning to Defer for clinical text (L2D-Clinical), a framework that learns when a BERT classifier should defer to an LLM based on uncertainty signals and […]